The popularity of Sildenafil initially sparked a period of growth for major pharmaceutical companies, however recent developments present a complicated picture for shareholders. Generic competitors are reducing earnings, and ongoing litigation add more complexity to the landscape. While certain companies could still benefit from complementary servi